ATTRACTION-2

NCT02267343 📎

Regimen

Experimental
nivolumab 3 mg/kg Q2W
Control
placebo

Population

East Asian patients with advanced gastric/GEJ cancer after >=2 prior lines of therapy

Key finding

mOS 5.26 vs 4.14 mo (HR 0.63, 95% CI 0.51-0.78, p<0.0001); 12-mo OS 26.2% vs 10.9%; ORR 11.2% vs 0%

Source: PMID 28993052

Timeline

    Guideline citations

    • NCCN GASTRIC (p.38)
    • CSCO GASTRIC 2025 (p.105)⚠️ OCR source